https://scholars.lib.ntu.edu.tw/handle/123456789/566357
標題: | Efficacy of clarithromycin-naproxen-oseltamivir combination therapy versus oseltamivir alone in hospitalized pediatric influenza patients | 作者: | Lee C.-W. Tai Y.-L. LI-MIN HUANG Chi H. Huang F.-Y. Chiu N.-C. Huang C.-Y. Tu Y.-H. Wang J.-Y. Huang D.T.-N. |
關鍵字: | Clarithromycin-naproxen-oseltamivir; Combination therapy; Influenza virus infection; Pediatric influenza | 公開日期: | 2020 | 出版社: | Elsevier Ltd | 來源出版物: | Journal of Microbiology, Immunology and Infection | 摘要: | Purpose: This study aimed to compare the safety and efficacy of clarithromycin-naproxen-oseltamivir combination therapy to that of oseltamivir therapy alone in hospitalized pediatric influenza patients. Methods: This prospective, single-blind study included children aged 1–18 years hospitalized with influenza, in MacKay Children's Hospital, Taiwan, between December 2017 and December 2019. The primary outcomes were the time to defervescence and decrease of the Pediatric Respiratory Severity Score (PRESS) during hospitalization. The secondary outcomes were serial changes in virus titers, measured using real-time polymerase chain reaction. Results: Fifty-four patients were enrolled (28 in the control group and 26 in the combination group) in total. There were no differences in the patients’ baseline characteristics between the groups. The time to defervescence was significantly shorter in the combination group than the oseltamivir group (13.2 h vs. 32.1 h, p = 0.002). The decrease in the virus titer from days 1–3 (log Δ13) was more pronounced in the combination group than the oseltamivir group. (39% vs. 19%, p = 0.001). There were no differences in adverse effects such as vomiting, diarrhea, and abdominal pain during the study or within 30 days after antiviral therapy. Conclusion: The clarithromycin-naproxen-oseltamivir combination group experienced a more rapid defervescence and a more rapid decline of influenza virus titer than the group treated with oseltamivir alone. Further consideration should be given to whether the overall benefits of combination therapy in hospitalized pediatric influenza patients outweigh the risks. ? 2020 |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85091862192&doi=10.1016%2fj.jmii.2020.08.017&partnerID=40&md5=b1b0f2badb608946aa4f127c59d53748 https://scholars.lib.ntu.edu.tw/handle/123456789/566357 |
ISSN: | 1684-1182 | DOI: | 10.1016/j.jmii.2020.08.017 | SDG/關鍵字: | amoxicillin plus clavulanic acid; azithromycin; clarithromycin; naproxen; oseltamivir; paracetamol; antivirus agent; clarithromycin; naproxen; nonsteroid antiinflammatory agent; oseltamivir; abdominal pain; antiviral therapy; Article; child; chill; combination drug therapy; controlled study; coughing; diarrhea; dizziness; drug efficacy; drug safety; dyspnea; female; headache; hospital patient; hospitalization; human; influenza; Influenza virus; major clinical study; male; myalgia; outcome assessment; pediatric patient; preschool child; prospective study; randomized controlled trial; real time polymerase chain reaction; rhinorrhea; school child; single blind procedure; sore throat; sputum; stridor; Taiwan; thorax pain; treatment response; virus load; vomiting; adolescent; combination drug therapy; drug effect; hospital; infant; influenza; pathology; treatment outcome; virology; Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Hospitalization; Hospitals, Pediatric; Humans; Infant; Influenza, Human; Male; Naproxen; Oseltamivir; Prospective Studies; Single-Blind Method; Treatment Outcome; Viral Load |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。